Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MOR210 |
Synonyms | |
Therapy Description |
MOR210 (TJ210) is a human antibody against complement component fragment 5a receptor (C5aR1, CD88), which may block C5aR1 signaling and induce anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MOR210 | TJ210|MPR 210|MOR-210|TJ 210|TJ-210|TJ210001|WBP2191 | MOR210 (TJ210) is a human antibody against complement component fragment 5a receptor (C5aR1, CD88), which may block C5aR1 signaling and induce anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04678921 | Phase I | MOR210 | Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | Completed | USA | 0 |